EP4615440A1 — Pyrrolopyrimidine compositions for treatment of itk mediated conditions
Assigned to Aclaris Therapeutics Inc · Expires 2025-09-17 · 1y expired
What this patent protects
The present disclosure relates to oral compositions of Compound I or a derivative thereof. Several dosing ranges are disclosed along with SAD, MAD and PK data. Comparative data between Compound I, Tofacitinib, Ritlecitinib, and Cyclosporine A are also disclosed. Methods of use fo…
USPTO Abstract
The present disclosure relates to oral compositions of Compound I or a derivative thereof. Several dosing ranges are disclosed along with SAD, MAD and PK data. Comparative data between Compound I, Tofacitinib, Ritlecitinib, and Cyclosporine A are also disclosed. Methods of use for treating an inflammatory condition are also disclosed.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.